Moreover, OPi, a novel OXPHOS complex I inhibitor, showed antitumor activity in MAPKi-resistant BRAF-mutant melanoma by promoting glycolytic metabolism and suppressing the TCA cycle through the LKB1-AMPK axis [55]. The gene discussed is BRAF; the disease is melanoma.